Search | Clinical Trials Finder

Conditions: Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
Interventions: Marijuana, Dronabinol, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Burlington, Vermont

Conditions: Posttraumatic Stress Disorder With Attention Defic
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Interventions: RQ-001, Placebo; Combination Product · Other
Lead sponsor: Red Queen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Barrett's Esophagus, Obesity
Interventions: Omega-3 polyunsaturated fatty acids, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions: Colesevelam, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
Interventions: Sucraid (sacrosidase) Oral Solution 8500 IU/mL; Biological
Lead sponsor: QOL Medical, LLC; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Los Angeles, California • Oakland, California • Coral Gables, Florida + 13 more

Conditions: Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions: Lofexidine HCl, Placebo, Open Label Lofexidine HCL; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years and older
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Clovis, California • Escondido, California • San Diego, California + 15 more

Conditions: Healthy Volunteers
Interventions: belatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Bipolar Disorder, Major Depressive Disorder
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions: Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions; Dietary Supplement · Other
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hurler Syndrome
Interventions: IRT Laronidase; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 6 Months to 3 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Phase 1 First-in-human Study Involving Healthy Subjects
Interventions: TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH); Drug · Biological
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more

Conditions: Hyperglycaemia (Diabetic)
Interventions: Dichloroacetate, Placebo oral capsule; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: Difamilast, Placebo; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Bacterial Infection
Interventions: MBN-101, Placebo; Drug · Other
Lead sponsor: Microbion Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 2 more

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Cataract
Interventions: Clobetasol propionate, Vehicle; Drug
Lead sponsor: Salvat; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Chandler, Arizona • Beverly Hills, California • Glendora, California + 19 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Juvenile; Scoliosis, Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis;Congenital, Kyphosis, Spondylolisthesis, Pectus Surgery, Hip Surgery
Interventions: Fast-Dissolve Melatonin Pill, Fast-Dissolve Placebo Pill; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: BSI-082, Trastuzumab deruxtecan; Drug · Other
Lead sponsor: Lei Zheng; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Scabies
Interventions: spinosad topical suspension, 0.9%, Placebo; Drug · Other
Lead sponsor: ParaPRO LLC; Industry
Eligibility: 4 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Elk Grove, California • Kissimmee, Florida • Miami, Florida + 1 more

Conditions: Head Lice
Interventions: Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 905 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

Atomoxetine and Executive Function in PTSD

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

Study Using Pregnenolone to Treat Bipolar Depression

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

Intrathecal Enzyme Replacement for Hurler Syndrome

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

Studying Melatonin and Recovery in Teens

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Clinical Endpoint Study of Ivermectin 0.5% Lotion